RT-qPCR positivity of WT1 in PB (cut-off > 0.5% after induction) was associated with a higher risk of 2-year CIR (74% vs. 38%, p = 0.00084) and a shorter OS (HR: 3.23, p = 0.0007) also in a later series of 183 AML patients [44], thus confirming the possibility to use PB as well as BM in patients in follow-up. Here, WT1 is linked to acute myeloid leukemia.